301015 logo

Qingdao Baheal Medical INC. Stock Price

SZSE:301015 Community·CN¥12.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

301015 Share Price Performance

CN¥24.08
-5.12 (-17.53%)
CN¥24.08
-5.12 (-17.53%)
Price CN¥24.08

301015 Community Narratives

There are no narratives available yet.

Snowflake Analysis

Excellent balance sheet, good value and pays a dividend.

0 Risks
3 Rewards

Qingdao Baheal Medical INC. Key Details

CN¥7.6b

Revenue

CN¥4.8b

Cost of Revenue

CN¥2.8b

Gross Profit

CN¥2.2b

Other Expenses

CN¥527.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
1.00
36.62%
6.96%
112.2%
View Full Analysis

About 301015

Founded
2005
Employees
3064
CEO
Gang Fu
WebsiteView website
www.baheal.cn

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Harle, and Wei Xi Kang brand names. It also provides ophthalmic drugs under the HYCOSAN brand name; tumor and other severe drugs under the Human Albumin and Xospata brand names; anti-aging and cosmeceuticals under the Quanis, Excellula, TRANSINO, and Qingchunbao brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; respiratory and anti-infective products under the Klacid brand name; and medical nutrition under the Nutrasumma brand name. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of BAHEAL Pharmaceutical Holdings Limited.

Recent 301015 News & Updates

Recent updates

No updates